An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
This review found that the best-quality evidence, across different conditions, estimated that CBT consistently produces a modest benefit in health-related quality of life.
1 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
2 Institute of Applied Health Research, University of Birmingham, Birmingham, UK
3 Faculty of Philosophy, University of Oxford, Oxford, UK
4 Department of Psychology and Logopedics, University of Helsinki, Helsinki, Finland
5 Department of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK
6 Institute of Mental Health, Nottinghamshire Healthcare NHS Foundation Trust, Nottingham, UK
7 Division of Psychiatry, University College London, London, UK
8 Department for Health, University of Bath, Bath, UK
9 Public and patient representative, Oxford, UK
10 Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
11 College of Medicine and Health, University of Exeter, Exeter, UK
* Corresponding author Email: beth.fordham@ndorms.ox.ac.uk
Declared competing interests of authors: Zafra Cooper reports occasional fees for lectures and workshops on cognitive–behaviour therapy (CBT) for eating disorders, and payment to provide various clinical and research groups with supervision in CBT for eating disorders. Roshan das Nair reports being chairperson of the National Institute for Health Research (NIHR) Research for Patient Benefit East Midlands Regional Advisory Committee (2019 to present); he was also a NIHR Health Services and Delivery Research funding panel member (2018–20). Sally Hopewell reports membership of the Health Technology Assessment (HTA) Clinical Evaluation and Trials Committee from 2018 to the present. Robert Howard reports grants from NIHR HTA and Efficacy and Mechanism Evaluation programmes during the conduct of the study. He was a member of the HTA Commissioning Committee (2013–18) and the HTA Commissioning Sub-board (2016–17). Milla Kaidesoja reports grants from the Helsinki Institute of Life Science during the conduct of the study. Sarah E Lamb was on the HTA Additional Capacity Funding Board (2012–15), the HTA End of Life Care and Add-on Studies Board (September 2015), the HTA Prioritisation Group Board (2010–15) and the HTA Trauma Board (2007–8).
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document